Alprostadil (Caverject/MUSE) Cost in Louisiana 2026

What Does Alprostadil Cost in Louisiana Right Now?

Brand alprostadil runs about $600 per month at Louisiana retail pharmacies in 2026, whether you are buying Caverject (intracavernosal injection) or MUSE (urethral suppository). Generic injectable alprostadil exists and can trim that price at some pharmacies, but the savings are inconsistent across chains. Cash prices at independent compounding pharmacies licensed under the 503A framework are the lowest available option for most Louisiana patients without commercial insurance coverage.

Alprostadil is a synthetic prostaglandin E1 analog. It works by relaxing smooth muscle and dilating cavernosal arteries, producing an erection within 5 to 20 minutes of administration. The landmark Linet et al. randomized controlled trial (N=296, NEJM 1996) demonstrated that intracavernosal alprostadil produced successful intercourse in 87% of injection attempts vs. 17% with placebo, establishing a high response rate that still informs prescribing today. The FDA first approved Caverject in 1995 and MUSE in 1996, and the drug has accumulated roughly three decades of post-market safety data.

Price variation across Louisiana ZIP codes is real. Baton Rouge and New Orleans metro pharmacies tend to have more competitive cash pricing because of higher pharmacy density, while rural parishes in northern Louisiana may see fewer options and slightly higher retail prices. Using a discount aggregator such as GoodRx or NeedyMeds can reduce the brand cash price at some chains, though the floor is typically $400 to $550 for a single 10-dose package of Caverject 10 mcg. The FDA prescribing information for Caverject confirms that doses range from 1.25 mcg to 60 mcg per injection, titrated in a clinical setting, so a monthly supply depends entirely on your prescribed dose and frequency.

Does Louisiana Medicaid Cover Alprostadil?

Louisiana Medicaid does not cover alprostadil for erectile dysfunction. This exclusion applies to both the Healthy Louisiana managed-care plans and to fee-for-service Medicaid. The exclusion is consistent with the approach most state Medicaid programs take toward drugs classified primarily as treatments for sexual dysfunction rather than for a listed covered condition.

The Centers for Medicare and Medicaid Services allows states to exclude drugs used for erectile dysfunction from their Medicaid formularies under the Social Security Act, Section 1927(d)(2). Louisiana exercises that exclusion. There is no current pending rule change that would reverse this for alprostadil specifically.

Patients who receive alprostadil for a primary indication other than erectile dysfunction (for example, as a diagnostic agent during penile Doppler ultrasound performed for vascular workup) may be able to request coverage under a different procedure code, but this is a narrow pathway and requires explicit documentation of the non-ED indication. A board-certified urologist or vascular specialist would need to support that documentation. The American Urological Association 2018 guideline on erectile dysfunction, endorsed by the Sexual Medicine Society of North America, recommends alprostadil as a second-line therapy after oral PDE5 inhibitors have failed or are contraindicated, which is the clinical framing most Louisiana providers use.

Medicare Part D also generally excludes erectile dysfunction drugs. Louisiana patients 65 and older on Medicare should not expect Part D coverage for Caverject or MUSE at a standard retail pharmacy.

Is Compounded Alprostadil Legal in Louisiana?

Yes. Compounded alprostadil is legal in Louisiana when prepared by a pharmacy operating under the federal 503A framework and holding a valid Louisiana Board of Pharmacy license. Louisiana follows standard federal compounding rules. A 503A pharmacy compounds on a patient-specific, prescription-by-prescription basis and may not manufacture large batches for office stock without a separate 503B outsourcing facility license.

The FDA defines 503A compounding pharmacies as those that compound drugs based on a valid prescription for an identified individual patient, exempt from cGMP requirements provided they meet USP standards. Louisiana-licensed 503A pharmacies can legally prepare alprostadil as an intracavernosal injection, often in tri-mix formulations that combine alprostadil with papaverine and phentolamine. The tri-mix option is not an FDA-approved product, but it is a well-established compounded preparation used by urologists across the country. A 2010 review in the Journal of Sexual Medicine documented tri-mix efficacy rates of 80 to 90% in patients who did not respond adequately to alprostadil monotherapy.

The cost advantage is significant. Compounded alprostadil or tri-mix from a Louisiana 503A pharmacy typically runs $50 to $150 per multi-dose vial, compared to the $600 monthly list price of brand Caverject. Some patients bring their monthly cost close to zero through patient assistance programs layered on top of compounded pricing, though those programs target branded products specifically.

One practical caution: compounded preparations are not bioequivalent to FDA-approved Caverject in a regulatory sense, and potency can vary between batches. Choose a 503A pharmacy that provides a certificate of analysis (COA) for each lot and that a licensed pharmacist has reviewed.

Which Private Insurance Plans Cover Alprostadil in Louisiana?

Coverage among commercial plans in Louisiana varies widely. Most employer-sponsored plans and ACA marketplace plans sold through the Louisiana Department of Insurance treat alprostadil as a specialty or non-formulary drug subject to prior authorization. A prior authorization (PA) for Caverject typically requires documentation that the patient has an organic erectile dysfunction diagnosis (usually an ICD-10 code of N52.x), that at least one PDE5 inhibitor has been tried and either failed or is contraindicated, and that a licensed prescriber (urologist or primary care physician) has submitted a PA form.

Blue Cross and Blue Shield of Louisiana, the state's largest commercial insurer, lists alprostadil under its specialty drug tier, which generally carries a 25 to 50% coinsurance after deductible rather than a flat copay. This means your out-of-pocket cost depends on whether you have met your deductible for the year. For a patient on a $3,000-deductible plan who has not yet met that deductible, a one-month supply of Caverject at $600 list price is a full $600 out of pocket before the plan pays anything.

United Healthcare, Aetna, and Cigna plans sold in Louisiana follow similar specialty tier logic. Humana Medicare Advantage plans sold in Louisiana generally mirror Part D exclusions and do not cover erectile dysfunction drugs. A specific Humana plan supplement rider might offer partial coverage; patients should call the plan's pharmacy benefit line to verify.

The AUA erectile dysfunction guideline recommends that physicians document organic etiology and prior treatment failure clearly in the patient record to support insurance authorization. A well-documented chart note substantially increases the likelihood of PA approval on the first submission.

How Do Manufacturer Savings Programs Work in Louisiana?

Pfizer offers a savings card for Caverject Impulse that reduces out-of-pocket costs for commercially insured patients. The card does not work for patients on Medicare, Medicaid, or any other federal or state government insurance program. Eligible patients with commercial insurance may pay as little as $0 to $50 per fill depending on the current program terms, though Pfizer periodically adjusts the maximum monthly benefit.

To use the card in Louisiana, a patient must be a U.S. resident, hold a valid commercial prescription insurance plan, and fill the prescription at a participating retail pharmacy. Most major chains in Louisiana (Walgreens, CVS, Walmart, Kroger, Winn-Dixie pharmacies) participate. The savings card is applied at the point of sale and does not require the patient to submit a separate claim.

Pfizer's patient assistance program (PAP), administered through the PfizerRxPathways portal, can provide Caverject at no cost to uninsured or underinsured Louisiana patients who meet income eligibility thresholds. Income limits for full assistance in 2025 were set at or below 400% of the federal poverty level, though limits are subject to annual revision. Patients who qualify may receive up to a 90-day supply at a time through mail delivery to a Louisiana address.

Generic alprostadil manufacturers do not universally offer comparable savings programs, so the Pfizer card's value is specifically tied to brand-name Caverject Impulse purchases.

Can You Get Alprostadil Via Telehealth in Louisiana?

Yes. Louisiana law permits telehealth prescribing of alprostadil by a licensed physician or advanced practice registered nurse (APRN) who has established a valid patient-provider relationship. After the federal public health emergency ended, CMS returned certain DEA-scheduled controlled substance prescribing to pre-pandemic in-person requirements, but alprostadil is not a DEA-scheduled controlled substance. The DEA drug scheduling list does not include alprostadil, so the telehealth prescribing flexibilities that expired for controlled substances do not apply here.

A Louisiana-licensed telehealth provider can review a patient's history of erectile dysfunction, confirm an organic etiology through questionnaire and medical records review, and issue a prescription without an in-person pelvic or genital exam in most clinical scenarios. The Louisiana State Board of Medical Examiners guidance on telehealth requires that the standard of care be met regardless of the delivery channel, which means the provider must document the diagnosis, prior treatment history, and contraindication assessment for PDE5 inhibitors before prescribing alprostadil as second-line therapy.

Injection training is one area where telehealth has a real limitation. The Caverject FDA label specifies that patients must receive initial injection training and their first dose in a clinical setting under medical supervision to assess hemodynamic response and rule out prolonged erection. MUSE (urethral suppository) has a lower training burden but still benefits from an initial in-office or supervised demonstration. HealthRX telehealth providers routinely coordinate with local Louisiana urology offices or urgent care clinics for this one-time supervised first-dose visit.

What Are the Cheapest Realistic Paths to Alprostadil in Louisiana?

The lowest-cost path depends on your insurance status.

Uninsured or Medicaid-only patients. A compounded alprostadil injection from a Louisiana 503A pharmacy is the most affordable route. A typical 10 mL multi-dose vial (enough for 10 to 20 injections depending on dose) costs $80 to $150. If you are uninsured and meet Pfizer income criteria, the PfizerRxPathways PAP can provide brand Caverject at no cost after a roughly two-week application review period.

Commercially insured patients. Submit the PA through your prescribing physician before your first fill. Use the Pfizer savings card if approved for brand Caverject. If the PA is denied, a formal appeal with supporting documentation from your urologist has a reasonable chance of reversal within 30 days. Meanwhile, compounded alprostadil from a 503A pharmacy requires only a standard prescription and no PA process.

Medicare patients. Neither Part D nor most Medicare Advantage plans in Louisiana cover alprostadil for erectile dysfunction. The Pfizer savings card is not eligible for use with Medicare. Compounded alprostadil from a 503A pharmacy is your most accessible cost-reduction option; the Medicare drug exclusion does not prohibit you from paying cash at a compounding pharmacy.

The table below organizes these pathways:

| Patient Type | Recommended Path | Estimated Monthly Cost | |---|---|---| | Uninsured, income <400% FPL | Pfizer PAP (brand Caverject) | $0 after approval | | Uninsured, income >400% FPL | 503A compounded alprostadil | $80 to $150 | | Commercially insured, PA approved | Brand Caverject + savings card | $0 to $50 | | Commercially insured, PA denied | 503A compounded alprostadil | $80 to $150 | | Medicare / Medicaid | 503A compounded alprostadil | $80 to $150 |

Clinical Pharmacology: Why Alprostadil Works When PDE5 Inhibitors Don't

Alprostadil acts on EP2 and EP3 prostaglandin receptors in cavernosal smooth muscle, triggering a cAMP-mediated relaxation cascade that is entirely independent of the nitric oxide/cGMP pathway that sildenafil, tadalafil, and vardenafil target. This mechanism explains why alprostadil remains effective in patients who have undergone radical prostatectomy, those with severe arterial insufficiency, and those on nitrate medications that would contraindicate oral PDE5 inhibitors. A 2004 review in the European Urology journal reported response rates of 70 to 80% for intracavernosal alprostadil in post-prostatectomy patients, a population where PDE5 inhibitor efficacy often drops below 50%.

Onset is faster than oral agents. Caverject injection produces erection within 5 to 20 minutes; MUSE suppository works in 5 to 10 minutes. Duration is 30 to 60 minutes at standard doses. Prolonged erection (priapism, defined as erection lasting more than four hours) is the most serious adverse effect, occurring in approximately 1% of patients on monotherapy alprostadil per the FDA label. Patients using compounded tri-mix may see slightly higher rates due to the papaverine component's additive effect. The AUA guideline recommends that patients be counseled to seek emergency care for any erection lasting beyond four hours, as permanent corporal fibrosis can result from ischemic priapism lasting six or more hours.

Dose titration starts at 1.25 to 2.5 mcg intracavernosal for neurogenic etiology and 2.5 to 5 mcg for vasculogenic etiology, titrated upward in-office in increments of 5 to 10 mcg until an adequate erectile response is achieved. Maximum recommended single dose is 60 mcg. Most patients find their effective dose between 10 and 20 mcg.

Alprostadil Safety Profile and Contraindications

Alprostadil is generally well tolerated. The most common adverse effect is penile pain, reported in 30 to 37% of patients in clinical trials, though most describe it as mild and transient. The Linet et al. NEJM trial (N=296) reported that penile pain occurred in 37.4% of the alprostadil group vs. 2.7% of the placebo group but led to study discontinuation in fewer than 4% of participants. Hematoma at the injection site occurs in approximately 5% of patients and is more common when injection technique is suboptimal.

Absolute contraindications include anatomical penile deformity (Peyronie's disease with severe curvature that complicates injection), conditions predisposing to priapism (sickle-cell disease, multiple myeloma, leukemia), and hypersensitivity to alprostadil. Relative contraindications include concurrent use of anticoagulants (warfarin, direct oral anticoagulants) where injection site bleeding risk is elevated. Alprostadil is not contraindicated with nitrates, unlike oral PDE5 inhibitors. This makes it a usable option for Louisiana patients managing concurrent cardiovascular disease with long-acting nitrates. The American Heart Association's scientific statement on sexual activity and cardiovascular disease confirms that intracavernosal alprostadil does not cause the systemic blood pressure drop seen with PDE5 inhibitor and nitrate co-administration.

MUSE (urethral suppository) has a distinct safety profile. The most common adverse effects are urethral burning (in approximately 36% of users) and minor urethral bleeding (in approximately 5%). MUSE is also contraindicated in patients with urethral stricture and requires that a partner use a condom if she is pregnant, because transdermal absorption of alprostadil in early pregnancy has not been fully characterized. The FDA label for MUSE documents these contraindications and precautions in detail.

How Louisiana Prescribers Typically Approach Alprostadil

Most Louisiana urologists follow the AUA ED guideline's stepwise model. Lifestyle modification and oral PDE5 inhibitors come first. Alprostadil enters the conversation when sildenafil (Viagra) and tadalafil (Cialis) have failed at maximum tolerated doses or are contraindicated. Some providers in the New Orleans and Baton Rouge metro areas have adopted vacuum erection device (VED) trials before alprostadil to satisfy insurer PA requirements, since some Louisiana plan PAs require documentation of VED failure as well.

Primary care physicians can prescribe alprostadil in Louisiana, but most defer the initial titration visit to a urologist or sexual medicine specialist because of the priapism monitoring requirement. After the first supervised injection, a patient can self-inject at home with the dose already established.

The International Society for Sexual Medicine (ISSM) guidelines state that intracavernosal injection therapy is the most effective non-surgical treatment for erectile dysfunction across all etiologies, with overall satisfaction rates of 70 to 87% in long-term observational studies. That figure covers patients who tolerate the injection technique. Roughly 10 to 20% of patients discontinue injection therapy within the first year due to technique anxiety, pain, or lack of partner support, not loss of drug efficacy.

Telehealth platforms like HealthRX that serve Louisiana patients typically coordinate with a local urology network for the supervised first-dose visit, then manage refills and dose adjustments remotely. This model keeps ongoing prescription costs down by reducing specialist visit fees while maintaining safety oversight for the first administration.

Checking Your Specific Louisiana Pharmacy Price Before You Fill

Retail alprostadil prices in Louisiana can vary by $100 to $200 between pharmacies on the same street. Before filling, take these three steps.

Check the GoodRx or RxSaver price at your specific ZIP code for both brand Caverject and any available generic alprostadil. Bring the coupon to the pharmacy counter and ask explicitly whether the cash-pay price with the coupon beats your insurance copay after deductible. For many patients mid-year on high-deductible plans, the coupon price is lower.

Call at least one Louisiana 503A compounding pharmacy. Ask for the price of alprostadil injection at your prescribed dose per vial. Ask whether they require the prescriber to send the prescription directly or whether you can forward it yourself. Most Louisiana 503A pharmacies accept electronic prescriptions from telehealth providers.

If your insurer denied a PA, request the denial in writing and note the specific denial reason code. Your prescriber can address each denial reason in a peer-to-peer appeal. Approximately 40 to 60% of specialty drug PA appeals in Louisiana are reversed on first peer-to-peer review when the prescriber participates directly.

Starting your prescription at a HealthRX Louisiana-licensed provider and requesting that the provider simultaneously submit a PA to your insurer and send a 503A compounding prescription as a backup reduces the gap between prescription and first fill to as little as 24 to 48 hours.